Thus, a loss of normal p53 function in CLL cells due to gene mutations or deletion (17p-deletion) would lead to elevated oxidative stress, and render the leukemia cells more vulnerable to further ROS stress induced by pharmacological agents. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.